Pick the Bottom, page-64

I seriously can't fathom the reason for looking in the rear-view mirror. It's the bio-tech industry and timelines are routinely broken due to factors outside individual companies control. Blaming management is just misguided as they can merely comply with the directives from the regulatory bodies to whom they are beholden. You know all this yet continue to somehow hold management at fault. Back in August/September, I recall reading a release from the company regarding the status of their platform which may help.
And you say the Prochymal initiative in Japan is small beer..agreed, however, I have seen estimates of 1500 cases in Japan and with therapy rumoured to cost around $150k, and with MSB likely to pick up a royalty of between 20%-30%, hardly a minor project.